InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Burrows Scott L | Chief Financial Officer | Sale | 12.5K | $71.37 | $892K | 98.0K | View ↗ | |
| 2026-05-01 | Sloan Sheldon | Chief Medical Officer | Sale | 78.3K | $71.50 | $5.60M | 0 | View ↗ | |
| 2026-05-01 | Turtle Cameron | Director & Chief Executive Officer | Sale | 15.0K | $71.37 | $1.07M | 612.5K | View ↗ | |
| 2026-04-01 | Turtle Cameron | Director & Chief Executive Officer | Sale | 15.0K | $49.33 | $740K | 627.5K | View ↗ | |
| 2026-03-02 | Turtle Cameron | Director & Chief Executive Officer | Sale | 15.0K | $42.19 | $633K | 642.5K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenue | $0 | $0-100.0% | $886K-62.0% | $2.3M-65.4% | $6.7M |
| Research and development | $171.7M+5.4% | $162.8M+81.9% | $89.5M+52.8% | $58.6M+2.6% | $57.1M |
| General and administrative | $47.9M+4.7% | $45.8M+14.6% | $39.9M+40.0% | $28.5M+4.4% | $27.3M |
| Acquired in-process research and development | $0 | $0-100.0% | $130.2M | $0 | $0 |
| Gain on sale of in-process research and development asset | -$10.0M | $0+100.0% | -$16.4M | $0 | $0 |
| Total operating expenses | $209.6M+0.5% | $208.6M-14.2% | $243.2M+179.2% | $87.1M+3.2% | $84.4M |
| Loss from operations | -$209.6M-0.5% | -$208.6M+13.9% | -$242.3M-185.8% | -$84.8M-29.1% | -$65.6M |
| Interest income | $24.9M+16.8% | $21.3M+246.7% | $6.1M+634.4% | $837K+654.1% | $111K |
| Other income (expense), net | $29.5M+242.2% | -$20.7M-8.3% | -$19.1M | — | — |
| Total other income (expense) | $54.3M+8972.5% | $599K+100.6% | -$96.5M-11728.1% | $830K | — |
| Loss before income tax expense | -$155.2M+25.4% | -$208.0M+38.6% | -$338.8M-303.6% | -$84.0M-27.9% | -$65.7M |
| Income tax benefit (expense) | $15K+129.4% | -$51K-296.2% | $26K | — | -$141K |
| Net loss | -$126.5M+15.4% | -$149.6M-57.6% | -$94.9M-13.2% | -$83.8M-27.4% | -$65.8M |
| Forward Contract Liability | |||||
| Change in fair value of forward contract liability | $0 | $0+100.0% | -$83.5M | $0 | $0 |
| Series A Non-Voting Convertible Preferred Stock | |||||
| Net loss | -$126.5M+15.4% | -$149.6M-57.6% | -$94.9M-13.2% | -$83.8M-27.4% | -$65.8M |
| Net loss per share, basic (in dollars per share) | -$1.98+37.7% | -$3.18+76.9% | -$13.76+99.9% | -$25K+0.6% | -$25K |
| Net loss per share, diluted (in dollars per share) | -$1.98+37.7% | -$3.18+76.9% | -$13.76+99.9% | -$25K+0.6% | -$25K |
| Weighted-average common shares outstanding, basic (in shares) | $64.1M+36.2% | $47.0M+581.9% | $6.9M-99.8% | $3.37B+28.2% | $2.63B |
| Weighted-average common shares outstanding, diluted (in shares) | $64.1M+36.2% | $47.0M+581.9% | $6.9M-99.8% | $3.37B+28.2% | $2.63B |
| Series B Non-Voting Convertible Preferred Stock | |||||
| Net loss | -$126.5M+15.4% | -$149.6M-57.6% | -$94.9M-13.2% | -$83.8M-27.4% | -$65.8M |
| Net loss per share, basic (in dollars per share) | -$1.98+37.7% | -$3.18+76.9% | -$13.76+99.9% | -$25K+0.6% | -$25K |
| Net loss per share, diluted (in dollars per share) | -$1.98+37.7% | -$3.18+76.9% | -$13.76+99.9% | -$25K+0.6% | -$25K |
| Weighted-average common shares outstanding, basic (in shares) | $64.1M+36.2% | $47.0M+581.9% | $6.9M-99.8% | $3.37B+28.2% | $2.63B |
| Weighted-average common shares outstanding, diluted (in shares) | $64.1M+36.2% | $47.0M+581.9% | $6.9M-99.8% | $3.37B+28.2% | $2.63B |
| Common Stock | |||||
| Net loss | -$126.5M+15.4% | -$149.6M-57.6% | -$94.9M-13.2% | -$83.8M-27.4% | -$65.8M |
| Net loss per share, basic (in dollars per share) | -$1.98+37.7% | -$3.18+76.9% | -$13.76+99.9% | -$25K+0.6% | -$25K |
| Net loss per share, diluted (in dollars per share) | -$1.98+37.7% | -$3.18+76.9% | -$13.76+99.9% | -$25K+0.6% | -$25K |
| Weighted-average common shares outstanding, basic (in shares) | $64.1M+36.2% | $47.0M+581.9% | $6.9M-99.8% | $3.37B+28.2% | $2.63B |
| Weighted-average common shares outstanding, diluted (in shares) | $64.1M+36.2% | $47.0M+581.9% | $6.9M-99.8% | $3.37B+28.2% | $2.63B |
| Development fee and royalty | |||||
| Total revenue | $0 | $0-100.0% | $886K-62.0% | $2.3M-65.4% | $6.7M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise
Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers